NSRX Insider Trade: Rubin Eyal CFO Options Filing May 2026

By Huzaifa Zahoor

May 1, 2026

6 min read

Share with:

preferred News SourceSelectMeykaasyourpreferredNewsSource

Key Points

Rubin Eyal files Form 3 initial ownership of 40,549 share options.

Options valued at $306,550 with $7.56 exercise price.

CFO compensation aligns with shareholder value creation.

Baseline filing enables tracking of future insider transactions.

Be the first to rate this article

Insider trading filings reveal what company leaders really think about their stock. When executives file ownership documents, it signals confidence or caution. Nasus Pharma Ltd. (NSRX) just reported a significant insider transaction involving Chief Financial Officer Rubin Eyal. On March 27, 2026, Eyal filed an initial ownership disclosure covering 40,549 share options valued at approximately $306,550. This Form 3 filing marks Eyal’s first official ownership report with the SEC. Understanding what this filing means helps investors gauge executive positioning and company leadership confidence.

Rubin Eyal’s Initial Ownership Filing Explained

Rubin Eyal, Chief Financial Officer of Nasus Pharma, filed a Form 3 on March 27, 2026. This is an initial ownership filing, not a buy or sell transaction. Form 3 filings document an insider’s first holdings when they join a company or assume a new role.

What Form 3 Means for Investors

Form 3 filings establish a baseline of insider ownership. They show what executives hold when they start reporting to the SEC. This filing doesn’t indicate buying or selling activity. Instead, it creates an official record of Eyal’s initial position. The 40,549 share options represent compensation granted to the CFO. At $7.56 per share, these options total approximately $306,550 in value. This baseline helps investors track future changes in executive holdings.

Share options give executives the right to buy shares at a set price. They differ from owning stock outright. Options can be valuable if the stock price rises above the exercise price. Eyal’s options represent future buying power, not immediate ownership. This structure aligns executive compensation with company performance. When options vest and executives exercise them, they become shareholders with voting rights.

Transaction Details and Valuation

The filing reveals specific details about Eyal’s option grant. The transaction date listed is November 20, 2026, though the filing occurred on March 27, 2026. This timing gap is common in initial ownership filings.

Option Grant Specifics

Eyal received 40,549 share options at an exercise price of $7.56 per share. The total estimated value reaches $306,550.44. This represents meaningful compensation for the CFO role. The option grant aligns Eyal’s interests with shareholder returns. If Nasus Pharma stock rises above $7.56, the options gain intrinsic value. Eyal benefits when the company performs well and stock price increases.

Market Context for NSRX

Nasus Pharma trades with a market cap of $23.3 million. The company carries a Meyka AI Grade of B, reflecting solid fundamentals relative to sector peers. This valuation context matters when evaluating executive compensation. A $306,550 option grant represents significant incentive alignment for a company of this size. The CFO’s compensation structure suggests confidence in long-term value creation.

What This Filing Signals About Leadership

Initial ownership filings provide insight into executive positioning and company structure. Eyal’s Form 3 filing marks his formal entry into SEC reporting requirements.

CFO Role and Responsibilities

As Chief Financial Officer, Eyal oversees financial strategy, reporting, and capital management. His option grant reflects the importance of this role. The $306,550 compensation package demonstrates Nasus Pharma’s commitment to attracting experienced financial leadership. CFOs typically receive substantial equity incentives to ensure long-term focus. Eyal’s options tie his compensation directly to shareholder value creation.

Insider Confidence Indicators

Form 3 filings alone don’t signal buying or selling pressure. However, they establish the foundation for tracking future insider activity. Investors should monitor whether Eyal exercises options, buys additional shares, or sells holdings. The initial grant shows the company values his leadership. Future filings will reveal whether Eyal increases or decreases his stake. This baseline filing enables meaningful analysis of executive behavior over time.

SEC Filing Details and Investor Resources

The SEC filing contains complete transaction documentation. Investors can access the full Form 3 through the SEC’s EDGAR database.

How to Access the Filing

The filing uses CIK number 0002029039 for Nasus Pharma. Rubin Eyal’s reporting CIK is 0001721411. These identifiers help locate filings in the SEC database. The March 27, 2026 filing date marks when the document was submitted. Investors can download the complete filing to review all details and attachments.

Understanding Form 3 Requirements

Form 3 filings are mandatory when insiders assume new roles or join companies. They must be filed within 10 days of the triggering event. The form discloses all securities owned, including options, restricted stock, and direct holdings. Eyal’s filing shows 40,549 share options as his initial reported position. Future Form 4 filings will track any changes to his holdings. This creates a transparent record of executive compensation and ownership.

Final Thoughts

Rubin Eyal’s Form 3 filing establishes his initial ownership position as Chief Financial Officer of Nasus Pharma. The 40,549 share options valued at $306,550 represent meaningful equity compensation aligned with shareholder interests. This initial ownership filing doesn’t signal buying or selling activity, but rather creates a baseline for tracking future insider transactions. Investors should monitor subsequent Form 4 filings to see whether Eyal exercises options, purchases additional shares, or sells holdings. The filing demonstrates Nasus Pharma’s commitment to executive compensation tied to long-term value creation. For investors tracking insider activity, this baseline filing…

FAQs

What is a Form 3 filing and why does it matter?

Form 3 is an initial insider ownership filing required when executives join a company. It establishes a baseline of holdings and enables tracking of future changes. Eyal’s Form 3 documents his 40,549 share options at the start of his CFO tenure.

What’s the difference between share options and stock ownership?

Share options grant executives the right to buy shares at a set price ($7.56 for Eyal). They’re not immediate ownership but become valuable if stock price rises, aligning executive compensation with company performance.

How much is Rubin Eyal’s option grant worth?

Eyal’s 40,549 share options are valued at approximately $306,550 based on the $7.56 exercise price, representing significant CFO compensation for Nasus Pharma.

When should I expect to see Eyal’s next insider filing?

Form 4 filings are required within two business days of any transaction. If Eyal exercises options, buys stock, or sells holdings, a Form 4 will be filed. Monitor SEC EDGAR for updates.

What does this filing tell us about Nasus Pharma’s outlook?

The option grant demonstrates Nasus Pharma values experienced financial leadership. The company’s solid fundamentals and Eyal’s compensation structure suggest confidence in long-term value creation and strategic growth.

Disclaimer:
The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Insider trading data is sourced from public SEC filings. This is not financial advice. Always conduct your own research and consult a licensed financial advisor before making investment decisions.